Print
Email
Print Edition StoriesTuesday, April 8, 2008
Idera lands patents for synthetic DNA
Idera Pharmaceuticals Inc. has won five patents worldwide related to its so-called immune modulatory oligonucleotides, which are synthetic DNA-based compounds intended to treat diseases.
The patents expand the Cambridge-based biotech firm's claims on the use of the DNA-based compounds to target Toll-like receptors, a family of proteins linked to immune responses in the body, company officials said. Included where two U.S. patents, two European patents, and one Australian patent.
Idera (Nasdaq: IDRA) said it has more than 220 issued or pending patients worldwide to cover compounds that target Toll-like receptors. With 38 employees, the firm reported a 2007 net loss of $13.2 million on revenue of $7.98 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
